P/E at 36.04 vs Industry's 34.89: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Norms

Sun Pharmaceutical Industries Ltd trades at a P/E of 36.04, slightly above the Pharmaceuticals & Biotechnology industry average of 34.89. This premium, though not extreme, suggests that investors are willing to pay a higher multiple for the stock relative to its peers. The valuation premium may reflect expectations of superior earnings growth or a perception of stronger fundamentals. However, the difference is narrow enough to warrant close scrutiny of performance metrics to justify this premium — previously rated Hold, what is Sun Pharma’s current rating?

Performance Across Timeframes: A Consistent Outperformer

Examining returns over various periods reveals Sun Pharmaceutical Industries Ltd has consistently outperformed the Sensex. Over one year, the stock gained 12.65%, while the Sensex declined by 8.19%. The year-to-date performance is similarly positive at 9.96%, contrasting with the Sensex’s 9.93% loss. Even over three months, the stock’s 7.61% rise slightly surpasses the Sensex’s 6.68% gain, indicating sustained momentum in the medium term.

Shorter-term returns also show strength. The stock rose 5.00% over the past month versus the Sensex’s 2.65%, and over the last week, it gained 1.24% compared to the Sensex’s 0.73%. On the day of reporting, Sun Pharma advanced 0.98%, outperforming the sector by 0.67%. This steady upward trend is supported by a two-day consecutive gain streak, accumulating 1.66% returns. Such consistent outperformance across multiple timeframes underscores the stock’s resilience — is this momentum sustainable or a temporary phase?

Moving Average Configuration: Bullish Technical Setup

The technical picture for Sun Pharmaceutical Industries Ltd is notably positive. The stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong upward trend. This configuration typically indicates robust buying interest and a bullish outlook from technical traders. Being close to its 52-week high, just 1.27% shy of Rs 1917.15, further reinforces the strength in price action.

Such a comprehensive moving average alignment often suggests that the stock is in a sustained recovery or continuation phase rather than a short-lived bounce — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 35 stocks that declared results, 19 reported positive outcomes, 9 were flat, and 7 posted negative results. This distribution suggests a cautiously optimistic environment for the sector, with a majority of companies showing resilience or growth. Sun Pharmaceutical Industries Ltd appears to be among the outperformers, given its consistent gains and premium valuation.

Rating Reassessment: From Hold to Buy

Previously rated Hold by MarketsMOJO, Sun Pharmaceutical Industries Ltd had its rating reassessed on 8 June 2026. While the current rating is not disclosed, the upgrade in Mojo Score to 74.0 and the shift from Hold indicate a more favourable view based on recent data. The rating change aligns with the stock’s strong relative performance and technical strength — should investors in Sun Pharma hold, buy more, or reconsider?

Market Capitalisation and Positioning

With a market capitalisation of approximately ₹4,53,714.24 crores, Sun Pharmaceutical Industries Ltd firmly holds its place as a large-cap stock within the Pharmaceuticals & Biotechnology sector. This scale provides it with significant market influence and access to capital, factors that often contribute to stability and growth potential. The stock’s proximity to its 52-week high further emphasises its strong market positioning.

Comparative Long-Term Returns

Looking beyond the recent year, the stock’s long-term returns are impressive. Over three years, it has delivered a 79.86% gain compared to the Sensex’s 18.60%. The five-year return is even more striking at 179.94%, significantly outpacing the Sensex’s 46.25%. However, over a ten-year horizon, the stock’s 147.64% return trails the Sensex’s 184.29%, indicating some relative underperformance in the longer term. This divergence may reflect sector-specific cycles or company-specific challenges in the past decade.

Short-Term Momentum vs Medium-Term Stability

The stock’s recent short-term momentum is supported by its technical indicators and daily gains, but the medium-term performance also shows steady appreciation. The 3-month return of 7.61% slightly exceeds the Sensex’s 6.68%, suggesting that the stock has maintained its upward trajectory without sharp volatility. This balance between short-term momentum and medium-term stability is a positive sign for investors seeking consistency — is this a sustainable trend or a temporary phase?

Conclusion: Data-Driven Insights on Sun Pharmaceutical Industries Ltd

The data paints a picture of Sun Pharmaceutical Industries Ltd as a large-cap stock trading at a slight valuation premium within its sector. Its consistent outperformance relative to the Sensex across multiple timeframes, combined with a bullish moving average configuration, suggests robust underlying momentum. The sector’s mixed results provide a backdrop against which the stock’s gains stand out. The recent rating reassessment from Hold to a more positive stance aligns with these data points, reflecting improved fundamentals and technical strength. Investors analysing this stock should consider how the valuation premium aligns with its sustained performance and technical indicators before making decisions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →